Camargo

SEPTEMBER 23, 2020

Panel Summary from the World Orphan Drug Congress 2020. Last month, executives from leading international biopharma companies came together at the World Orphan Drug Congress 2020 to discuss how they are evaluating new opportunities in the rare disease space. Thomas Kassberg, Chief Business Officer, Ultragenyx.

Business Development 136

Business Development Drugs Development Production 136

pharmaphorum

SEPTEMBER 8, 2020

Exelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug conjugates reinforces a recent change of direction for the biotech. The latest partnerships are with Swiss startup NBE-Therapeutics and Catalent Pharma, and boost Exelixis’ ADC capabilities in multiple areas.

Antibody 52

Antibody Licensing Licensing Drugs 52

The Pharma Data

NOVEMBER 23, 2020

OSLO, Norway–( BUSINESS WIRE )– Ultimovacs ASA (“Ultimovacs”, ticker ULTIMO), today announced that Ton Berkien will join Ultimovacs’ management team as Chief Business Officer (CBO), effective December 1, 2020. Mr. Berkien is currently a board member of the Nordic Pharma Licensing Group.

Business Development 52

Business Development Clinical Trials Clinical Trials Licensing 52

The Pharma Data

OCTOBER 20, 2020

MBA, as the Company’s Chief Business Officer following the retirement of Wenji Chen, PhD, MBA, from her position as Vice President of Corporate Development. Earlier in his career, he ran business-development functions at Amgen and Baxter.

Licensing 40

Licensing Licensing Drug Delivery Business Development 40

pharmaphorum

OCTOBER 1, 2021

The debut – raising upwards of £350 million from new shares – is the largest IPO for a UK biotech company since allergy drug specialist Circassia in 2014. It may also use the cash injection for “in-licensing opportunities and potential acquisitions”, according to the document.

Marketing 52

Marketing Business Development Genome Genomics 52

The Pharma Data

JUNE 7, 2023

LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery. Acuitas’ proprietary LNP technology is used in multiple vaccines and therapeutics in clinical development and was also used in some of the COVID-19 vaccines that were approved and administered to people in 180 countries. .

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

pharmaphorum

AUGUST 24, 2020

With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius and its pipeline of drugs for cancer and fibrotic diseases.

Immune Response 59

Immune Response Antibody Drugs Licensing 59

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. Food and Drug Administration cleared an Investigational New Drug application for a Phase I study of pluripotent stem cell-derived dopaminergic neurons in advanced Parkinson’s disease.

Gene Therapy 52

Gene Therapy Gene Gene Editing Licensing 52

Drug Discovery World

JANUARY 23, 2024

Hardiman, Senior Director, Ventures – Business Development at Astellas, weighed in: “You’ve got to be intentional and creative to raise funds. As an R&D pipeline and business develops in an increasingly multi-disciplinary sector, new competencies are required to progress.

Life Science 59

Life Science Business Development Protein Development 59

Drug Discovery World

JANUARY 30, 2024

Natalia Elizalde, Chief Business Development Officer, VIVEbiotech, says that Dr Naldini’s award represents the significant benefits and demonstrated safety of the therapies developed using lentiviral vectors that are being used for more and more clinical trials and more prevalent diseases.

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond.

Licensing 52

Licensing Licensing Medicine Development 52

The Pharma Data

AUGUST 21, 2020

Fortunately, as a member of the Novartis Business Development & Licensing (BD&L) department, she was in a position to try to help. She joined the Novartis COVID-19 R&D Task Force to help tackle the emerging pandemic, taking the reins of the business development workstream.

Business Development 52

Business Development Licensing Licensing Development 52

pharmaphorum

DECEMBER 14, 2022

Angelini Ventures will lend its network and knowledge of the life sciences industry to “strengthen the bridge between the excellence of Italian academic research and the development of drug discovery programmes in order to identify new treatment options,” said Angelini Industries CEO Professor Sergio Marullo di Condojanni in a statement.

Life Science 105

Life Science Development Business Development Genetics 105

The Pharma Data

AUGUST 17, 2021

Effective September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology. The company recently announced Breakthrough Therapy designation for donanemab and its intention to submit a biologics license application (BLA) under the accelerated approval pathway later this year.

Medicine 52

Medicine Dermatology Production Development 52

The Pharma Data

NOVEMBER 25, 2020

Shafi Khan , Burkhan World’s VP of Business Development stated, “Burkhan is honoured to have partnered up with Vivera in supporting its efforts globally in the medical supply sector. With management expertise in hospitality and finance, the Burkhan World Group of Companies, based in Washington D.C. ,

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Manufacturing Licensing 52

The Pharma Data

NOVEMBER 10, 2020

Furthermore, data show that the class of drug substances being developed within AlzeCure’s platform, so-called gamma-secretory modulators, selectively affect the production of toxic Abeta-amyloid, without affecting the cleavage of other substrates that potentially play an important role in normal physiological function.

Development 40

Development Drugs Protein Research 40

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. billion the drug generated in 2021. Pfizer’s total global revenue in 2022 from Comirnaty was $37.81

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

NOVEMBER 3, 2020

Food and Drug Administration (FDA) has granted Fast Track designation to its clinical candidate, LB-001 for the treatment methylmalonic acidemia (MMA). Fast Track designation allows for early and frequent communication with the FDA throughout the entire drug development and review process. About LogicBio Therapeutics.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

The Pharma Data

OCTOBER 27, 2020

DermSafe is listed by Health Canada under its approved products “ Disinfectants and hand sanitizers accepted under COVID-19 interim measure ” and has two Drug Identification Numbers (DIN) for personal use and personal commercial use. Statements have not been evaluated by Health Canada. SOURCE: Ovation Science Inc. .

Sales 52

Sales Production Drug Delivery Development 52

The Pharma Data

DECEMBER 8, 2020

AbCellera’s AI-powered antibody discovery platform speeds the otherwise lengthy and grueling process by analyzing the database of natural immune systems to find antibodies that can be developed into drugs. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost.

RNA 52

RNA Antibody Life Science Protein 52

The Pharma Data

JANUARY 12, 2021

As part of this role he built innovative, high-performing development teams and managed the Regeneron’s regulatory filings, interactions with regulatory agencies, product launches, and business development and licensing activities across its product portfolio. We are delighted to have Dr. Graham join the Tiziana team.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Pharmaceutical Technology

JULY 23, 2008

It has boosted anti-tumour research by 60% since 2005, at a cost of $1.6bn, in the hope of increasing the share of company sales attributed to cancer drugs from the current level of 5% “There are a lot of patients that are suffering,” said Pfizer chief executive Jeffrey Kindler.

Sales 130

Sales Drugs Marketing Licensing 130

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

The Pharma Data

NOVEMBER 5, 2020

Prior to that, Taveras was vice president of Small Molecule Drug Discovery and CMC Development at Biogen Idec, and Alantos Pharmaceuticals, which was acquired by Amgen in 2007. Prior to this, he held a position as a director of Analytical Chemistry in Drug Discovery at GlaxoSmithKline. from 1993 to 1995.

Genome 40

Genome Genomics Medicine Life Science 40

The Pharma Data

AUGUST 3, 2021

Revenue growth was 12 percent when excluding effects of 2020 COVID-related stocking patterns, revenue from COVID-19 antibodies and recent business development. Business Development/Other Developments. In the second quarter of 2021, the company recognized acquired in-process research and development charges of $25.0

Antibody 52

Antibody Sales Production Development 52

The Pharma Data

JANUARY 4, 2021

. Kiromic’s deep understanding of the tumor micro environment (TME) and the tumors’ escape and masking mechanisms led to development of a promising platform for chimeric antigen receptor therapy (CAR-T). We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University.

In-Vivo 40

In-Vivo Development Big Data Immune Response 40

The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. In the United States, the division benefited particularly from the launch of the cancer drug Nubeqa™. percent.

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

JANUARY 27, 2021

Finalized the technical development of modia , a digital therapy for opioid use disorder, for which Orexo owns the exclusive global rights. Entered an exclusive license and supply agreement with Accord Healthcare for ZUBSOLV® covering 29 European countries. Important events after the period.

Production 52

Production Marketing Sales Licensing 52

Drug Discovery World

NOVEMBER 9, 2023

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Simone Oostindie, PhD, Director, Research and Discovery, Gyes, on: ‘Avidity engineering: A next frontier in the development of differentiating antibody therapeutics’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

OCTOBER 26, 2020

billion related to certain license and collaboration agreements, and certain other items. The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation. Business Developments. Business Developments.

Sales 40

Sales Vaccination Vaccine Production 40

The Pharma Data

NOVEMBER 5, 2020

resolving patent litigation brought in response to Teva’s Abbreviated New Drug Application, seeking approval to market a generic version of Xtampza ER prior to the expiration of Collegium’s applicable patents. Reached a settlement with Teva Pharmaceutical USA, Inc.

Production 52

Production Marketing Sales Manufacturing 52

The Pharma Data

NOVEMBER 5, 2020

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for the treatment of patients 12 years and older with eosinophilic esophagitis (EoE). Corporate and Business Development Update. The Company commenced delivery of REGN-COV2 drug product under the agreement during the third quarter of 2020.

Sales 52

Sales Production Manufacturing Antibody 52

The Pharma Data

AUGUST 3, 2021

Research & Development (R&D) expenses increased 12% primarily due to higher research and early pipeline spend and late-stage development program spend, including our recent business development activities. The FDA has assigned a Prescription Drug User Fee Act action date of December 19, 2021. billion to $5.0

Sales 52

Sales Production Antibody Development 52

The Pharma Data

JANUARY 17, 2021

The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory. SPR206 is in clinical development as an innovative option for the treatment of multi-drug resistant (MDR) Gram-negative bacterial infections. SHANGHAI , Jan. ” About SPR206.

Medicine 52

Medicine Clinical Development Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 8, 2020

It is estimated that there will potentially be 13 million moderate-to-severe acne patients treated with oral antibiotics in the urban Chinese population by 2028, which represents a significant opportunity to launch an innovative product whose clinical development is largely de-risked.

Dermatology 52

Dermatology Sales Marketing Production 52

The Pharma Data

OCTOBER 15, 2020

The committee is tasked with supporting BeyondSpring’s business development activities related to its lead asset, Plinabulin, and other pipeline assets. Mukul Agarwal, former vice president of Corporate Development, at Forty Seven, Inc., Floyd co-founded Elion Oncology which licensed PCS6422 to Processa.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52

The Pharma Data

DECEMBER 17, 2020

George Yeh, President of TLC, commenced the conference and welcomed the company’s new Chief Business Officer, Mr. Tom Bliss. With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Containment 40